DOI:
10.1055/s-00000030
Der Klinikarzt
LinksClose Window
References
Martin M, Holmes FA, Ejlertsen B. et al.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast
cancer (ExteNET): 5-year analysis of a randomised, double-blind,
placebo-controlled, phase 3 trial.
Lancet Oncol 2017;
18: 1688-1700
We do not assume any responsibility for the contents of the web pages of other providers.